Hinova Pharmaceuticals Inc. (SHA:688302)
China flag China · Delayed Price · Currency is CNY
42.60
+1.98 (4.87%)
At close: Mar 6, 2026

Hinova Pharmaceuticals Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2018
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2018
Market Capitalization
4,1624,8693,0415,1563,992-
Upgrade
Market Cap Growth
34.58%60.11%-41.02%29.14%--
Upgrade
Enterprise Value
3,3514,0582,1413,9912,299-
Upgrade
Last Close Price
42.0349.1730.7152.0740.32-
Upgrade
PS Ratio
201.30235.508289.18-2418.38-
Upgrade
PB Ratio
3.784.422.553.772.52-
Upgrade
P/TBV Ratio
3.894.552.623.862.57-
Upgrade
EV/Sales Ratio
162.10196.305837.54-1392.58-
Upgrade
Debt / Equity Ratio
0.100.100.010.010.020.01
Upgrade
Net Debt / Equity Ratio
-0.74-0.74-0.70-0.80-0.97-1.14
Upgrade
Net Debt / EBITDA Ratio
6.066.063.703.264.432.62
Upgrade
Net Debt / FCF Ratio
--3.023.083.993.62
Upgrade
Asset Turnover
--0-0.00-
Upgrade
Inventory Turnover
--66.31-134.51-
Upgrade
Quick Ratio
--5.7510.3411.354.71
Upgrade
Current Ratio
--6.0310.7411.654.99
Upgrade
Return on Equity (ROE)
-11.92%-11.92%-15.59%-19.93%-25.40%-34.50%
Upgrade
Return on Assets (ROA)
---9.98%-13.04%-16.00%-19.89%
Upgrade
Return on Capital Employed (ROCE)
---18.80%-24.30%-21.80%-43.60%
Upgrade
Earnings Yield
-3.28%-2.81%-6.56%-5.71%-7.55%-
Upgrade
FCF Yield
---9.10%-6.88%-9.62%-
Upgrade
Buyback Yield / Dilution
0.20%0.20%-0.21%-9.06%-22.21%-5.74%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.